Bispecific T-cell engager (TCE) therapy currently has limited data regarding its associated cardiovascular complications, despite known risks with other cancer immunotherapies.
Does bispecific T-cell engager therapy increase cardiovascular adverse events?
Bispecific T-Cell Engager (TCE) therapy
Cardiovascular adverse eventssafety
Data on cardiovascular complications associated with T-cell engager therapy remain limited.
Although some cancer immunotherapies have been linked to increased cardiovascular risk, data on T-cell engager (TCE) therapy–associated cardiovascular complications remain limited.
Building similarity graph...
Analyzing shared references across papers
Loading...
Osnat Itzhaki Ben Zadok
Shai Shimony
Shannon M. Miller
JACC CardioOncology
Harvard University
Brigham and Women's Hospital
Dana-Farber Cancer Institute
Building similarity graph...
Analyzing shared references across papers
Loading...
Zadok et al. (Sun,) reported a other. Bispecific T-cell engager (TCE) therapy currently has limited data regarding its associated cardiovascular complications, despite known risks with other cancer immunotherapies.
www.synapsesocial.com/papers/69ba426d4e9516ffd37a2a40 — DOI: https://doi.org/10.1016/j.jaccao.2026.01.005